LLY250110P755000
- 0.13
- -1.62-92.57%
Eli Lilly and Co Newsroom
Medicare Expands Coverage of Eli Lilly's Weight-Loss Drug -- WSJ
Drugs Not Selected for Medicare Price Negotiation Nearly Doubled - Report
Medicare Can Cover Zepbound for Sleep Apnea, Creating a Significant Opportunity for Eli Lilly
Medicare Will Pay for Zepbound for Some Patients. The Costs Could Be Huge -- Barrons.com
Novo, Eli Lilly to Dominate Global Pharma Sales in 2025: Report
LLY Falls Around 14% in 3 Months: How to Play the Stock
Express News | Eli Lilly - New Centre Expected to Open in Mid-2025
Express News | Lilly - to Establish New Global Capability Centre in Hyderabad, India
S&P 500 Positive for 'First Five Days,' Huang Sees Decades till Quantum | Wall Street Today
Express News | CMS: With FDA Approved Use for Zepbound to Treat Obstructive Sleep Apnea, Current Medicare Part D and Medicaid Coverage Rules Apply
'Medicare Can Now Cover Eli Lilly's Zepbound For Sleep Apnea, CMS Says' - CNBC
Wednesday Market Falls, Quantum Computing Pulls Back Hard on Treasury Yield Crunch | Live Stock
Novo Nordisk Needs Answers to These 5 Key Questions
Truist Financial Maintains Eli Lilly and Co(LLY.US) With Buy Rating, Maintains Target Price $1,029
What Trump's Denmark Tariff Threat Means for Ozempic Drugmaker Novo Nordisk
Tuesday Market Pulls Back After Nvidia All Time High | Wall Street Today
These Stocks Are Expected to See at Least 25% Revenue Growth in 2025 – Wolfe
FDA Issues Draft Guidance on Developing Weight Loss Drugs
Citi Says 'Buy' These Stocks in '25; SA Quant Ratings Says Maybe Not
Market Sells CES Tech News, ISM Tuesday as Nvidia Champions Robots Monday | Live Stock